Skip to main content
BGI Genomics Co., Ltd. logo

BGI Genomics Co., Ltd. — Investor Relations & Filings

Ticker · 300676 ISIN · CNE100003449 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 1,656 across all filing types
Latest filing 2019-01-31 Major Shareholding Noti…
Country CN China
Listing Shenzhen Stock Exchange 300676

About BGI Genomics Co., Ltd.

https://www.bgi.com

BGI Genomics Co., Ltd. is a leading provider of integrated solutions for precision medicine, specializing in genomic sequencing and proteomic services. The company offers a comprehensive portfolio of clinical diagnostics and research services across various fields, including reproductive health, oncology, and infectious diseases. Key products include non-invasive prenatal testing, hereditary cancer screening, and pathogen identification tools. Leveraging proprietary DNBseq sequencing technology, BGI Genomics provides high-throughput, cost-effective genomic data analysis to healthcare providers, research institutions, and pharmaceutical companies worldwide. The organization focuses on advancing personalized medicine through large-scale genomic research and the development of innovative diagnostic applications, aiming to improve health outcomes by making advanced genetic insights accessible to a global population.

Recent filings

Filing Released Lang Actions
关于持股5%以上股东重要事项的公告
Major Shareholding Notification Classification · 95% confidence The document is an announcement regarding changes in the shareholding structure of a shareholder holding more than 5% of the company's shares. It details changes in the capital contributions and partnership interests of key shareholders and partners, including current and former directors and senior management. The document does not contain financial statements or detailed financial performance data. It is a notification about significant shareholding changes, specifically about a shareholder holding more than 5% of shares and changes in their internal structure. Therefore, it fits the category of Major Shareholding Notification (MRQ). The document length is short and focused on shareholding changes, not a full report or financial disclosure.
2019-01-31 Chinese
关于控股股东部分股权解除质押及再质押的公告
Capital/Financing Update Classification · 100% confidence The document is a public announcement from Shenzhen BGI Genomics Co., Ltd. regarding the partial release and re-pledging of shares by its controlling shareholder. It details the number of shares released from pledge, re-pledged shares, pledge dates, pledgees, and risk warnings related to share pledging. The document is short (1353 characters) and focuses on share pledge transactions by a major shareholder, which is a capital structure related update. It does not contain financial statements or detailed financial performance data, nor is it a report or presentation. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2019-01-31 Chinese
第二届董事会第六次会议决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of the resolutions passed at the sixth meeting of the second board of directors of Shenzhen BGI Genomics Co., Ltd. It details the meeting's convening, attendance, and voting results on specific corporate matters such as waiving the preemptive rights on subsidiary shares and calling an extraordinary general meeting. The content focuses on board decisions and governance procedures rather than financial results or reports. The document length is 1871 characters, which is relatively short and consistent with a meeting resolution announcement rather than a full report. There is no financial data or detailed financial analysis present. Therefore, this document fits best under the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors.
2019-01-30 Chinese
独立董事关于第二届董事会第六次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from independent directors regarding a specific board meeting matter about waiving the preemptive rights on subsidiary shares and related party transactions. It references compliance with stock exchange rules and company articles but does not contain financial statements or detailed financial data. It is a governance-related document focused on board decisions and opinions rather than a full report or announcement of financial results. Therefore, it fits best under Board/Management Information (MANG). The document length is short and focused on board opinions, not a full report or announcement.
2019-01-30 Chinese
中信证券股份有限公司关于公司放弃控股子公司股权优先购买权暨关联交易的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed opinion and verification report from CITIC Securities regarding Shenzhen BGI Genomics Co., Ltd.'s decision to waive its preemptive rights to purchase equity in a controlling subsidiary, which constitutes a related party transaction. It includes extensive information about the transaction, parties involved, financial data, legal and regulatory compliance, board and independent directors' opinions, and the sponsor's verification opinion. The document is not a financial report like an annual or interim report, nor is it a simple announcement. It is a formal audit or verification opinion related to a specific transaction and regulatory compliance, fitting the definition of an Audit Report / Information (AR). The length and detail confirm it is not a brief announcement or certification but a substantive report on the transaction and its compliance. 9M 2018
2019-01-30 Chinese
独立董事关于第二届董事会第六次会议相关事项的事前认可意见
Board/Management Information Classification · 95% confidence The document is a formal opinion from independent directors regarding a specific board meeting agenda item about waiving the preemptive purchase rights of a controlling subsidiary's equity and related party transactions. It references regulatory guidelines for independent directors and board meeting procedures. The content is focused on board/management matters and approvals rather than financial results, audit, or shareholder voting outcomes. The document length is short and it is not an announcement of a report publication or a certification. Therefore, it fits best under Board/Management Information (MANG).
2019-01-30 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.